Novartis

5 stories about Novartis
ילד חולה ילדים חולים

Ayala Pharmaceuticals Raises $30 Million

29.05.19|Adi Pick
The Israel-based company intends to use the new round of funding to advance the clinical development of its anti-cancer product
אחות אחיות רפואה סיעוד

Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals

24.12.18|Lilach Baumer
The investment is part of a licensing option agreement signed between the two companies
תרופה מזרק אפיפן מיילן אלרגיה

Teva, Mylan Drop on Announcement of Epinephrine Injector Rival

09.12.18|Lilach Baumer
Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
המדען הראשי ב כלל ביוטכנולוגיה ד"ר ג'וליאן אדמס

Pharma Veteran Julian Adams takes Helm at Gamida Cell

21.11.17|Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor